AUR-106

N/A

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NameAUR-106
Drug Alias NameAUR-106
ClassificationSmall molecules
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitorsProgrammed death-ligand 1 blockers
TargetsT cell immunoglobulin and ITIM domainsProgrammed death-ligand 1
Therapy Area/IndicationsKidney NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAurigene Discovery Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAurigene Discovery Technologies IncAurigene Discovery Technologies Ltd
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A